Sildenafil Strips – Orally Disintegrating Strip (viagra strips)

Each carton contains 4 or 8 pouches.

The product is an opaque light blue, thin, flexible oral film with film imprint code, and characteristic lemon and grapefruit flavor with the following dimensions: Recommended Storage:Store at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

Disclosure statement

placebo; p-value <0.001 IIEF= International Index of Erectile Function, EF = Erectile Function, SEP Q2=Sexual Encounter Profile Question 2, SEP Q3 = Sexual Encounter Profile Question 3, N = Number of Subjects, SD = Standard Deviation, LS = Least Squares, CI = Confidence Interval. Sildenafil was assessed in many clinical studies for its effect on the ability of men with ED to engage in sexual activity and in many cases specifically on the ability to achieve and maintain an erection sufficient for satisfactory sexual activity. Sildenafil was evaluated primarily at doses of 25 mg, 50 mg and 100 mg in 21 randomized, double-blind, placebo-controlled trials of up to 6 months in duration, using a variety of study designs (fixed dose, titration, parallel, crossover). Sildenafil was administered to more than 3,000 patients aged 19 to 87 years, with ED of various etiologies (organic, psychogenic, mixed) with a mean duration of 5 years. sildenafil citrate demonstrated statistically significant improvement compared to placebo in all 21 studies.

4.1. Manufacturing of ODTs

The studies that established benefit demonstrated improvements in success rates for sexual intercourse compared with placebo. Sildenafil Efficacy Results from Controlled Clinical Studies The effect of sildenafil on one of the major end points, maintenance of erections after penetration, is shown in Figure 7, for the pooled results of 5 sildenafil fixed-dose, dose-response studies of greater than one-month duration, showing response according to baseline function. Results with all doses have been pooled, but scores showed greater improvement at the 50 and 100 mg doses than at the 25 mg dose. The pattern of responses was similar for the other principal question, the ability to achieve an erection sufficient for intercourse. The titration studies, in which most patients received 100 mg, showed similar results. Advise the patient to read the FDA-approved patient labeling ( Patient Information) Advise patients to place SILDENAFIL ORAL FILM directly onto the tongue where it will disintegrate and can then be swallowed with saliva without the need for water or other liquids. Advise patients not to cut or chew SILDENAFIL ORAL FILM [seeDosage and Administration (2.4) ].

Physicians should discuss with patients the contraindication of SILDENAFIL ORAL FILM with regular and/or intermittent use of nitric oxide donors, such as organic nitrates or organic nitrites in any form [see Contraindications (4.1)].

People who purchased S-FILM Orally Disintegrating Strip also bought

One randomized, double-blind, placebo-controlled, crossover, flexible-dose (up to 100 mg) sildenafil study of patients with erectile dysfunction resulting from spinal cord injury (n=178) was conducted. The changes from baseline in scoring on the two endpoint questions (frequency of successful penetration during sexual activity and maintenance of erections after penetration) were highly statistically significantly in favor of sildenafil. On a global improvement question, 83% of patients reported improved erections on sildenafil versus 12% on placebo. Diary data indicated that 59% of attempts at sexual intercourse were successful on sildenafil compared to 13% on placebo. Across all trials, sildenafil improved the erections of 43% of radical prostatectomy patients compared to 15% on placebo.

5.1 Cardiovascular Risk

Subgroup analyses of responses to a global improvement question in patients with psychogenic etiology in two fixed-dose sildenafil studies (total n=179) and two sildenafil titration studies (total n=149) showed 84% of sildenafil patients reported improvement in erections compared with 26% of placebo. The changes from baseline in scoring on the two endpoint questions (frequency of successful penetration during sexual activity and maintenance of erections after penetration) were highly statistically significantly in favor of sildenafil .Diary data in two of the studies (n=178) showed rates of successful intercourse per attempt of 70% for sildenafil and 29% for placebo. Efficacy Results in Subpopulations in Controlled Clinical Studies A review of population subgroups in sildenafil studies demonstrated efficacy regardless of baseline severity, etiology, race and age. Sildenafil was effective in a broad range of ED patients, including those with a history of coronary artery disease, hypertension, other cardiac disease, peripheral vascular disease, diabetes mellitus, depression, coronary artery bypass graft (CABG), radical prostatectomy, transurethral resection of the prostate (TURP) and spinal cord injury, and in patients taking antidepressants/antipsychotics and antihypertensives/diuretics. SILDENAFIL ORAL FILM is supplied as oral films in individually sealed foil pouches in four dosage strengths. Physicians should discuss with patients the contraindication of SILDENAFIL ORAL FILM with use of guanylate cyclase stimulators such as riociguat [see Contraindications (4.3)].

• Sildenafil oral strips provide a non-invasive way to treat ED.
• They avoid swallowing pills, which some patients find difficult.
• Strips are often manufactured with pleasant flavors to enhance appeal.
• The medication’s effect can be influenced by food intake.
• Alcohol consumption may reduce effectiveness or increase side effects.
• Sildenafil strips should be used as prescribed and not mixed with other ED drugs.
• These strips are designed for quick absorption in the oral mucosa.
• Overuse or misuse can lead to adverse health effects.
• Proper dosing helps minimize risks of prolonged erections or priapism.
• Sildenafil strips do not cure ED but help manage symptoms.
• They may be used in combination with psychological or lifestyle interventions.
• Always check expiration dates before using sildenafil strips.

Concomitant Use with Drugs Which Lower Blood Pressure Physicians should advise patients of the potential for SILDENAFIL ORAL FILM to augment the blood pressure lowering effect of alpha-blockers and antihypertensive medications. Concomitant administration of SILDENAFIL ORAL FILM and an alpha blocker may lead to symptomatic hypotension in some patients.

• Sildenafil strips are an alternative to traditional pill forms.
• The strips dissolve quickly, eliminating need for water to swallow.
• They are convenient for on-the-go use and discreet consumption.
• Possible side effects include headache, flushing, and dizziness.
• Sildenafil strips should be used approximately one hour before activity.
• Not suitable for individuals with certain health conditions; consult a doctor.
• They are typically used in men aged 18 and above.
• The medication works by increasing blood flow to the penis.
• Sildenafil strips can be part of a broader erectile dysfunction treatment plan.
• Side effects may vary depending on individual health status.
• Erectile response may improve with proper use and dosing.
• They are available through licensed pharmacies and online sources.

Therefore, when SILDENAFIL ORAL FILM is co-administered with alpha-blockers, patients should be stable on alpha-blocker therapy prior to initiating SILDENAFIL ORAL FILM treatment and SILDENAFIL ORAL FILM should be initiated at the lowest dose [see Warnings and Precautions (5.5)].

• Sildenafil oral strips are a fast-acting form of erectile dysfunction medication.
• They are administered orally, dissolving quickly on the tongue for rapid effect.
• Sildenafil strips are often flavored to improve the user experience.
• They contain the same active ingredient as traditional sildenafil tablets.
• These strips are designed for people seeking discreet medication options.
• Onset of action for sildenafil strips can be within 15-30 minutes.
• Proper storage of sildenafil strips involves keeping them in a cool, dry place.
• Dosage strength varies, typically available in 25mg, 50mg, and 100mg.
• Using sildenafil strips without medical consultation is not recommended.
• They may interact with other medications like nitrates or alpha-blockers.
• Sildenafil oral strips are approved for the treatment of erectile dysfunction.
• Users should follow prescribed dosages for safety and effectiveness.

Physicians should discuss with patients the potential cardiac risk of sexual activity in patients with preexisting cardiovascular risk factors. Patients who experience symptoms (e.g., angina pectoris, dizziness, nausea) upon initiation of sexual activity should be advised to refrain from further activity and should discuss the episode with their physician [see Warnings and Precautions (5.1)].

Author contributions

Figure 7 shows that regardless of the baseline levels of function, subsequent function in patients treated with sildenafil was better than that seen in patients treated with placebo. At the same time, on-treatment function was better in treated patients who were less impaired at baseline. Figure7: Effect of Sildenafil and Placebo on Maintenance of Erection by Baseline Score The frequency of patients reporting improvement of erections in response to a global question in four of the sildenafil randomized, double-blind, parallel, placebo-controlled fixed dose studies (1797 patients) of 12 to 24 weeks duration is shown in Figure 8. These patients had erectile dysfunction at baseline that was characterized by median categorical scores of 2 (a few times) on principal IIEF questions. Erectile dysfunction was attributed to organic (58%; generally not characterized, but including diabetes and excluding spinal cord injury), psychogenic (17%), or mixed (24%) etiologies.

Altitude sickness

Sixty-three percent, 74%, and 82% of the patients on 25 mg, 50 mg and 100 mg of sildenafil, respectively, reported an improvement in their erections, compared to 24% on placebo. In the titration studies (n=644) (with most patients eventually receiving 100 mg), results were similar. Figure8: Percentageof Patients Reportingan Improvement in Erections The patients in the sildenafil studies had varying degrees of ED. One-third to one-half of the subjects in these studies reported successful intercourse at least once during a 4-week, treatment-free run-in period. In many of the sildenafil studies, of both fixed dose and titration designs, daily diaries were kept by patients. Physicians should advise patients to stop use of all PDE5 inhibitors, including SILDENAFIL ORAL FILM and seek medical attention in the event of a sudden loss of vision in one or both eyes.

Oral Strips

In these studies, involving about 1600 patients, analyses of patient diaries showed no effect of sildenafil on rates of attempted intercourse (about 2 per week), but there was clear treatment-related improvement in sexual function: per patient weekly success rates averaged 1.3 on 50-100 mg of sildenafil vs 0.4 on placebo; similarly, group mean success rates (total successes divided by total attempts) were about 66% on sildenafil citrate vs about 20% on placebo. During 3 to 6 months of double-blind treatment or longer-term (1 year), open-label sildenafil studies, few patients withdrew from active treatment for any reason, including lack of effectiveness. At the end of the long-term study, 88% of patients reported that sildenafil improved their erections. Men with untreated ED had relatively low baseline scores for all aspects of sexual function measured canada sildenafil (again using a 5-point scale) in the IIEF. Sildenafil improved these aspects of sexual function: frequency, firmness and maintenance of erections; frequency of orgasm; frequency and level of desire; frequency, satisfaction and enjoyment of intercourse; and overall relationship satisfaction.

8.4 Pediatric Use

One randomized, double-blind, flexible-dose, placebo-controlled sildenafil study included only patients with erectile dysfunction attributed to complications of diabetes mellitus (n=268). As in the other titration studies, patients were started on 50 mg and allowed to adjust the dose up to 100 mg or down to 25 mg of sildenafil; all patients, however, were receiving 50 mg or 100 mg at the end of the study. There were highly statistically significant improvements on the two principal IIEF questions (frequency of successful penetration during sexual activity and maintenance of erections after penetration) on sildenafil compared to placebo. On a global improvement question, 57% of sildenafil patients reported improved erections versus 10% on placebo. Diary data indicated that on sildenafil, 48% of intercourse attempts were successful versus 12% on placebo.